(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing - 2Beyond oil: The crucial exports blocked by Hormuz closure
- 3How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
- 4The 25 Most Notable Style Crossroads in History
- 5RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- 4 injured in shooting at North Carolina tree lighting ceremony
- How to watch ‘The Traitors’ Season 4: Premiere date, episode release time, full cast list and more
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- Why won't NASA's Artemis 2 astronauts land on the moon when they get there?
- 7 Countries Where You Can Buy a Home for Under $100,000
- Germany raises prospect of military forces to secure Ukraine peace
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- Countdown begins for long-awaited Artemis II moon mission
